• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Novartis AG

    10/17/24 4:01:28 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVS alert in real time by email
    SC 13D/A 1 tm2410988d42_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment no. 6)*

     

    MORPHOSYS AG

    (Name of Subject Company (Issuer))

     

    NOVARTIS BIDCO GERMANY AG

    an indirect wholly owned subsidiary of

     

    NOVARTIS AG

    (Name of Filing Persons (Offerors))

     

    Ordinary Shares, no Par Value

    (Title of Class of Securities)

     

    617760202

    (CUSIP Number of Class of Securities)

     

    Karen L. Hale
    Chief Legal Officer
    Novartis AG
    Lichstrasse 35
    CH-4056 Basel
    Switzerland
    Telephone: +41-61-324-1111
    Fax: +41-61-324-7826

    (Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)

     

    With a copy to:

    Jenny Hochenberg
    Freshfields Bruckhaus Deringer US LLP
    601 Lexington Ave.
    New York, NY 10022
    Telephone: +1 646 863-1626
    ​ Doug Smith
    Freshfields Bruckhaus Deringer LLP
    100 Bishopsgate
    London EC2P 2SR
    United Kingdom
    +44 20 7936 4000

     

     

     

    October 15, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note:    Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 617760202SCHEDULE 13D 

     

    1.   Names of Reporting Person
    Novartis BidCo Germany AG
    I.R.S. Identification No. of above person (entities only)
     
    2.   Check the Appropriate Box if a Member of a Group   (a) x
                    (b)  ¨
     
    3.   SEC Use Only            
     
    4.   Source of Funds (See Instructions)
    OO, AF
     
    5.   Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)
                    ¨ 
     
    6.   Citizenship or Place of Organization
    Switzerland
     
                 
    Number of
    Shares
      7.   Sole Voting Power
    0
       
    Beneficially    
    Owned by
    Each
      8.   Shared Voting Power
    37,716,423
       
    Reporting    
    Person
    With
      9.   Sole Dispositive Power
    0
       
             
            10.   Shared Dispositive Power
    37,716,423
       
     
    11.   Aggregate Amount Beneficially Owned by Each Reporting Person
    37,716,423
     
    12.   Check if the Aggregate Amount in Row (11) Excludes Certain Shares    
                    ¨ 
     
    13.   Percent of Class Represented by Amount in Row (11)
    100.00%(1) 
     
    14.   Type of Reporting Person (See Instructions)
    CO
     

    (1) The calculation of the foregoing percentage is based on 37,716,423 outstanding bearer shares (“Shares”) with no-par value (and including Shares held in treasury) of MorphoSys AG (the “Issuer”). 

     

       2

     

     

    CUSIP No. 617760202SCHEDULE 13D 

     

    1.   Names of Reporting Person
    Novartis BidCo AG

    I.R.S. Identification No. of above person (entities only)
     
    2.   Check the Appropriate Box if a Member of a Group   (a) x
                    (b)  ¨
     
    3.   SEC Use Only            
     
    4.   Source of Funds (See Instructions)
    OO, AF
     
    5.   Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)
                    ¨ 
     
    6.   Citizenship or Place of Organization
    Switzerland
     
                 
    Number of
    Shares
      7.   Sole Voting Power
    0
       
    Beneficially    
    Owned by
    Each
      8.   Shared Voting Power
    37,716,423
       
    Reporting    
    Person
    With
      9.   Sole Dispositive Power
    0
       
             
            10.   Shared Dispositive Power
    37,716,423
       
     
    11.   Aggregate Amount Beneficially Owned by Each Reporting Person
    37,716,423
     
    12.   Check if the Aggregate Amount in Row (11) Excludes Certain Shares    
                    ¨ 
     
    13.   Percent of Class Represented by Amount in Row (11)
    100.00%(2) 
     
    14.   Type of Reporting Person (See Instructions)
    CO
     

    (2) The calculation of the foregoing percentage is based on 37,716,423 outstanding Shares (and including Shares held in treasury).

     

       3

     

     

    CUSIP No. 617760202SCHEDULE 13D 

     

    1.   Names of Reporting Person
    Novartis Pharma AG
    I.R.S. Identification No. of above person (entities only)
     
    2.   Check the Appropriate Box if a Member of a Group   (a) x
                    (b)  ¨
     
    3.   SEC Use Only            
     
    4.   Source of Funds (See Instructions)
    OO, AF
     
    5.   Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)
                    ¨ 
     
    6.   Citizenship or Place of Organization
    Switzerland
     
                 
    Number of
    Shares
      7.   Sole Voting Power
    0
       
    Beneficially    
    Owned by
    Each
      8.   Shared Voting Power
    37,716,423
       
    Reporting    
    Person
    With
      9.   Sole Dispositive Power
    0
       
             
            10.   Shared Dispositive Power
    37,716,423
       
     
    11.   Aggregate Amount Beneficially Owned by Each Reporting Person
    37,716,423
     
    12.   Check if the Aggregate Amount in Row (11) Excludes Certain Shares    
                    ¨ 
     
    13.   Percent of Class Represented by Amount in Row (11)
    100.00%(3) 
     
    14.   Type of Reporting Person (See Instructions)
    CO
     

    (3) The calculation of the foregoing percentage is based on 37,716,423 outstanding Shares (and including Shares held in treasury).

     

       4

     

     

    CUSIP No. 617760202SCHEDULE 13D 

     

    1.   Names of Reporting Person
    Novartis AG
    I.R.S. Identification No. of above person (entities only)
     
    2.   Check the Appropriate Box if a Member of a Group   (a) x
                    (b)  ¨
     
    3.   SEC Use Only            
     
    4.   Source of Funds (See Instructions)
    OO, AF
     
    5.   Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)
                    ¨ 
     
    6.   Citizenship or Place of Organization
    Switzerland
     
                 
    Number of
    Shares
      7.   Sole Voting Power
    0
       
    Beneficially    
    Owned by
    Each
      8.   Shared Voting Power
    37,716,423
       
    Reporting    
    Person
    With
      9.   Sole Dispositive Power
    0
       
             
            10.   Shared Dispositive Power
    37,716,423
       
     
    11.   Aggregate Amount Beneficially Owned by Each Reporting Person
    37,716,423
     
    12.   Check if the Aggregate Amount in Row (11) Excludes Certain Shares    
                    ¨ 
     
    13.   Percent of Class Represented by Amount in Row (11)
    100.00%(4) 
     
    14.   Type of Reporting Person (See Instructions)
    CO
     

    (4) The calculation of the foregoing percentage is based on 37,716,423 outstanding Shares (and including Shares held in treasury).

     

       5

     

     

    Explanatory Note

     

    This Amendment No. 6 (the “Amendment No. 6”) amends the statement on Schedule 13D originally filed by the Reporting Persons on April 18, 2024. The Items below amend the information disclosed under the corresponding Item of the Schedule 13D as described below. Except as specifically provided herein, this Amendment No. 6 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined herein shall have the meanings attributed to them in the Schedule 13D.

     

    Item 2. Identity and Background

     

    Item 2 of the Schedule 13D is hereby amended by supplementing it with the following:

     

    On October 15, 2024, the Purchaser acquired 2,108,003 Shares as a result of the merger squeeze-out (as defined below) for an aggregate price of EUR 68.00.

     

    Item 4. Purpose of the Transaction

     

    The section entitled “Squeeze-out under stock corporation law, merger squeeze-out under transformation law” of Item 4 of the Schedule 13D is hereby amended by supplementing it with the following new paragraph:

     

    The Purchaser has acquired more than 90% of the Shares enabling it to effect a merger squeeze-out (as defined below) under German law. On August 27, 2024, the Issuer announced that its shareholders approved all resolutions proposed by the Issuer’s Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of the Issuer’s minority shareholders’ shares to Novartis BidCo Germany AG, a subsidiary of the Purchaser, against a cash compensation of €68.00 per share (the “merger squeeze-out”). The merger squeeze-out is effective as of October 15, 2024, following the transfer resolution and merger having been registered in the commercial register of the Issuer, and the merger has also having been registered in the commercial register of Novartis BidCo Germany AG.

     

    Item 5. Interest in Securities of the Issuer

     

    Item 5(a) of the Schedule 13D is hereby amended and restated in its entirety to read as follows:

     

    (a) and (b)—The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. The Purchaser is the direct beneficial owner of 37,716,423 Shares as of 9:00 a.m. New York time on October 15, 2024, representing 100.00% of all Shares (including Shares represented by ADSs and Shares held in treasury).

     

    None of the Reporting Persons nor, to the knowledge of the Reporting Persons, any person named in Item 2 hereof has beneficial ownership of any Shares, except as set forth on Schedule B or otherwise described in this Schedule 13D.

     

    (c)—None of the Reporting Persons nor, to the best knowledge of the Reporting Persons, any person named in Item 2 hereof, has engaged in any transaction during the past 60 days in, any Shares, except as set forth on Schedule B or otherwise described in this Schedule 13D.

     

    (d)— Except as described in this Schedule 13D, to the knowledge of the Reporting Persons, none of the Reporting Persons nor any of the persons set forth on Schedule A hereto has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    (e)—Not applicable.

     

    Schedule B

     

    On October 15, 2024, the Purchaser acquired a total of 2,108,003 Shares as a result of the merger squeeze-out for an aggregate price of EUR 68.00.

     

       6

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 17, 2024

     

    Novartis BidCo Germany AG  
       
    By: /s/ Jan-Hendrik Petersen  
      Name: Jan-Hendrik Petersen  
      Title: As Authorized Signatory  

     

    Novartis BidCo AG    
         
    By: /s/ Daniel Weiss   /s/ Bertrand Bugnon
      Name: Daniel Weiss   Name: Bertrand Bugnon
      Title: As Authorized Signatory   Title: As Authorized Signatory
         
    Novartis Pharma AG    
         
    By: /s/ Lukas Foertsch   /s/ Christian Rehm
      Name: Lukas Foertsch   Name: Christian Rehm
      Title: As Authorized Signatory   Title: As Authorized Signatory

     

    Novartis AG    
         
    By: /s/ David Quartner   /s/ Tariq ElRafie
      Name: David Quartner    Name: Tariq ElRafie
      Title: As Attorney   Title: As Attorney

     

       7

     

    Get the next $NVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVS

    DatePrice TargetRatingAnalyst
    2/13/2025Buy → Neutral
    UBS
    2/12/2025Underweight
    Morgan Stanley
    2/4/2025Hold → Buy
    Deutsche Bank
    12/4/2024Hold → Reduce
    HSBC Securities
    9/11/2024$135.00 → $130.00Buy → Neutral
    BofA Securities
    9/5/2024Buy → Neutral
    Goldman
    9/3/2024Buy → Hold
    Jefferies
    7/19/2024Buy → Hold
    Deutsche Bank
    More analyst ratings

    $NVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Barbara Weber, M.D., Elected to ITM Supervisory Board

      Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex

      4/9/25 5:00:00 AM ET
      $BNTX
      $GSK
      $NVS
      $RLAY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

      Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program1Phase III data showed Vanrafia achieved proteinuria reduction of 36.1% (P<0.0001) vs. placebo with improvements seen at Week 6 and sustained through Week 36 and favorable safety1,2IgAN is a progressive, rare kidney disease; up to 50% of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis3-9With third FDA approval in under 1 year across its renal portfolio, Novartis is uniquely positioned to lead a transformation in kidney careEAST HANOVER, N.J., April 2, 2025 /PRNewswire/ -- N

      4/2/25 8:29:00 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

      Phase III study showed sustained proteinuria reduction at one year with favorable safety1Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presenceEAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G),

      3/20/25 7:37:00 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    SEC Filings

    See more
    • SEC Form 6-K filed by Novartis AG

      6-K - NOVARTIS AG (0001114448) (Filer)

      4/29/25 6:01:32 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novartis AG

      6-K - NOVARTIS AG (0001114448) (Filer)

      4/2/25 9:35:17 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novartis AG

      6-K - NOVARTIS AG (0001114448) (Filer)

      3/28/25 2:01:26 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    Financials

    Live finance-specific insights

    See more
    • PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

      - PTC to receive $1.0B in cash at closing -- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -- PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NY

      12/2/24 7:00:00 AM ET
      $NVS
      $PTCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

      JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULESJUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTIONTHE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBETHE PARTNERSHIP IS FOUNDED ON JUST - EVOTEC BIOLOGICS' AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ' LEADING BIOSIMILARS PIPELINE AND CAP

      5/9/23 2:30:00 PM ET
      $EVO
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ligand Reports First Quarter 2023 Financial Results

      2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

      5/4/23 4:01:00 PM ET
      $ANEB
      $LGND
      $NOVN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Novartis AG

      SC 13D/A - NOVARTIS AG (0001114448) (Filed by)

      10/17/24 4:01:28 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Novartis AG downgraded by UBS

      UBS downgraded Novartis AG from Buy to Neutral

      2/13/25 8:48:14 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Novartis AG

      Morgan Stanley initiated coverage of Novartis AG with a rating of Underweight

      2/12/25 7:07:04 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novartis AG upgraded by Deutsche Bank

      Deutsche Bank upgraded Novartis AG from Hold to Buy

      2/4/25 7:05:09 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $NVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 1, 2024 - FDA Roundup: November 1, 2024

      For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

      11/1/24 3:18:19 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care